SLC17A2 inhibitors are a class of chemical compounds that specifically target and inhibit the function of the SLC17A2 protein, a member of the solute carrier family. SLC17A2 is part of the larger SLC17 family, which is known for its role in transporting organic anions, including neurotransmitters and other small molecules, across cellular membranes. The inhibition of SLC17A2 can disrupt the transport processes it mediates, offering researchers a powerful tool to study the protein's function and its broader impact on cellular activities. By selectively inhibiting SLC17A2, scientists can explore how this transporter influences the distribution and concentration of specific anions within cells, and how these changes affect cellular metabolism and signaling.
The use of SLC17A2 inhibitors in research is particularly valuable for dissecting the role of this transporter in various biological systems. By blocking SLC17A2 activity, researchers can observe the resulting alterations in cellular processes, such as changes in ion gradients, neurotransmitter release, and intracellular signaling pathways. These studies help to elucidate the specific substrates transported by SLC17A2 and the physiological contexts in which this transporter is most active. Additionally, SLC17A2 inhibitors can be used to explore the regulatory mechanisms that control the expression and activity of this protein, providing insights into how cells maintain homeostasis in response to environmental and intracellular cues. Through these investigations, SLC17A2 inhibitors contribute to a deeper understanding of membrane transport mechanisms and the complex interplay between transport proteins and cellular function.
SEE ALSO...
Items 1 to 10 of 19 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
D(−)-2-Amino-5-phosphonovaleric acid (D-AP5) | 79055-68-8 | sc-200434 | 5 mg | $97.00 | 2 | |
As an NMDA receptor antagonist, AP5 can indirectly influence glutamate signaling and release. | ||||||
6-Cyano-7-nitroquinoxaline-2,3-dione | 115066-14-3 | sc-505104 | 10 mg | $208.00 | 2 | |
CNQX is a potent AMPA receptor antagonist, indirectly affecting glutamate signaling and release. | ||||||
Kynurenic acid | 492-27-3 | sc-202683 sc-202683A sc-202683B | 250 mg 1 g 5 g | $26.00 $57.00 $138.00 | 6 | |
This is a broad-spectrum antagonist for excitatory amino acid receptors, thus reducing glutamate signaling. | ||||||
Riluzole | 1744-22-5 | sc-201081 sc-201081A sc-201081B sc-201081C | 20 mg 100 mg 1 g 25 g | $20.00 $193.00 $213.00 $317.00 | 1 | |
Riluzole inhibits the release of glutamate, influencing the function of SLC17A7 indirectly. | ||||||
Ethosuximide | 77-67-8 | sc-211431 | 1 g | $306.00 | ||
This compound reduces T-type calcium channel activity, which can indirectly influence glutamate release. | ||||||
Lamotrigine | 84057-84-1 | sc-201079 sc-201079A | 10 mg 50 mg | $120.00 $486.00 | 1 | |
Lamotrigine inhibits voltage-sensitive sodium channels, leading to a decrease in glutamate release. | ||||||
Topiramate | 97240-79-4 | sc-204350 sc-204350A | 10 mg 50 mg | $107.00 $369.00 | ||
It modulates GABA-evoked currents, indirectly influencing glutamate release. | ||||||
Felbamate | 25451-15-4 | sc-203579 sc-203579A | 10 mg 50 mg | $101.00 $373.00 | ||
Felbamate acts as a NMDA receptor antagonist, indirectly affecting glutamate signaling and release. | ||||||
FCCP | 370-86-5 | sc-203578 sc-203578A | 10 mg 50 mg | $94.00 $355.00 | 46 | |
A protonophore, disrupts proton gradients, potentially influencing SLC17A function. | ||||||
Niflumic acid | 4394-00-7 | sc-204820 | 5 g | $32.00 | 3 | |
A nonsteroidal anti-inflammatory drug, may indirectly affect ion channels and transporters like SLC17A. | ||||||